Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 3/20 | 0.58 |
| ▸ | CDK1 | P06493 | 7/20 | 0.43 |
| ▸ | CDK2 | P24941 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12720382 | 1.00 | FLT4 (0.58) | FLT4CDK1CDK2KDRCDK4 | |
| SCHEMBL1627765 | 1.00 | FLT4 (0.58) | FLT4CDK1CDK2KDRCDK4 | |
| SCHEMBL15513049 | 0.86 | FLT4 (0.47) | FLT4CDK1CDK2KDRCDK4 | |
| SCHEMBL17429758 | 0.85 | FLT4 (0.46) | FLT4CDK1CDK2KDRCDK4 | |
| SCHEMBL30895328 | 0.85 | PTK2 (0.47) | CDK1CDK2KDRCDK4PTK2 | |
| Bromide SCHEMBL30895402 | 0.83 | PTK2 (0.46) | FLT4CDK1CDK2KDRCDK4 | |
| SCHEMBL1628013 | 0.82 | PTK2 (0.52) | KDRPTK2 | |
| SCHEMBL1008313 | 0.81 | PTK2 (0.53) | KDRPTK2AURKAGSK3AGSK3B | |
| SCHEMBL11987611 | 0.81 | AURKA (0.46) | CDK1CDK2KDRCDK4CCNB1 | |
| SCHEMBL15524187 | 0.78 | FLT4 (0.73) | FLT4PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-8440822-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. | 2013-05-14 | — | — | US | disclosed |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER, INC. | 2013-01-03 | — | — | US | disclosed |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER, INC. | 2013-01-03 | — | — | US | disclosed |
| US-8247411-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2146779-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008129380-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | FLT4 1928/4885CDK1 310/4885CDK2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.